Your session is about to expire
← Back to Search
CAR T-cell Therapy
Adoptive Cellular Therapy for Pediatric Brain Tumors (IMPACT Trial)
Phase 1
Waitlist Available
Led By Eugene Hwang, MD
Research Sponsored by Children's National Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Organ function: ANC ≥750/µL, Absolute lymphocyte count (ALC) >500/μL, Platelets ≥75K, Bilirubin ≤3xULN, Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) <5x upper limit of normal (ULN), Serum creatinine ≤1.0mg/dL or 1.5x ULN for age (whichever is higher), Pulse oximetry >90% on room air
Parent(s)/guardian(s) capable of providing informed consent
Must not have
Patients with uncontrolled infections
Patients with medulloblastoma of the SHH subtype
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Summary
"This trial is testing a new treatment for young children with brain tumors who cannot undergo radiation therapy. The treatment involves using the patient's own immune cells to target specific proteins found in the tumor. The study
Who is the study for?
This trial is for children under 5 with certain brain tumors (like medulloblastoma, pineoblastoma) who can have a device called an Ommaya reservoir placed in their brain. They should be able to handle the procedure to collect blood cells and have enough tumor tissue available. Their body must be functioning well overall, with acceptable blood counts and organ function.
What is being tested?
The IMPACT study tests personalized immune cells (TSA-T) designed to target specific proteins on a child's own brain tumor. It's after standard treatments like chemo. The goal is to see if these custom-made cells are safe and how they affect the tumor and the child's immune system.
What are the potential side effects?
Potential side effects aren't specified here but generally, therapies using T-cells could cause reactions at infusion sites, flu-like symptoms, changes in blood pressure or heart rate, allergic reactions, or more serious immune responses affecting different organs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My parent or guardian can give consent for me.
Select...
I have been newly diagnosed with a specific type of brain tumor.
Select...
I am under 5 years old.
Select...
I can do most activities but may need help.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any infections that aren't responding to treatment.
Select...
My medulloblastoma is of the SHH subtype.
Select...
I am taking more than 0.05mg/kg of dexamethasone.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Any unexpected toxicity of grade ≥3 attributed to the infusion of TSA-T
Grade ≥3 infusion-related adverse event
Grade ≥3 pneumonitis, uveitis
+2 moreSecondary outcome measures
Overall survival
Progression free survival
TSA-T responses
Trial Design
1Treatment groups
Experimental Treatment
Group I: Embryonal brain tumorsExperimental Treatment1 Intervention
These patients are young children (<5 years of age) with newly diagnosed high-risk embryonal CNS malignancies and are expected to have a modest male predominance reflecting the sex-based incidence of pediatric brain tumors. Patients will have a Lansky performance status of ≥60.
Find a Location
Who is running the clinical trial?
Children's National Research InstituteLead Sponsor
214 Previous Clinical Trials
253,524 Total Patients Enrolled
Eugene Hwang, MDPrincipal InvestigatorChildren's National Research Institute
4 Previous Clinical Trials
131 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger